Universities of Cologne

Researchers demonstrated that combining trametinib and rapamycin, two existing cancer drugs, extends mouse lifespan by approximately 30%, significantly more than either drug alone.

New data from the PROVE study reveals cefiderocol achieves better clinical outcomes when used as empiric (64.6%) or documented therapy (67.4%) compared to salvage therapy (58.2%) in serious gram-negative infections.

The MATTERHORN trial demonstrated that transcatheter edge-to-edge repair (TEER) is non-inferior to surgery in treating secondary mitral regurgitation (MR) at one year.